Quest Diagnostics (DGX) Tops Q4 EPS by 24c
Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $4.48, $0.24 better than the analyst estimate of $4.24. Revenue for the quarter came in at $3 billion versus the consensus estimate of $2.93 billion.
Outlook for First Half of 2021
The company estimates its first half 2021 results as follows:
Low | High | |||
Net revenues | $4.85 billion | $5.15 billion | ||
Net revenues increase | 32.9% | 41.1% | ||
Reported diluted EPS | $5.07 | 6.07 | ||
Adjusted diluted EPS | $5.90 | $6.90 | ||
Cash provided by operations | At least $800 million | |||
Capital expenditures | Approximately $200 million | |||
Note on Non-GAAP Financial Measures
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.